Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + filgrastim + rituximab
- Development stage
- Phase 3
- Lead developer
- Baxter
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
This is a combination therapy regimen that includes:
- Cyclophosphamide: An alkylating agent that damages DNA and prevents cell division
- Filgrastim (G-CSF): A granulocyte colony-stimulating factor that stimulates bone marrow to produce neutrophils and stem cells
- Rituximab: A monoclonal antibody targeting CD20 on B cells
The combination is used primarily for:
1. Treatment of non-Hodgkin lymphoma, particularly in older patients 2. Stem cell mobilization prior to autologous stem cell transplantation 3. Treatment of ANCA-associated vasculitis 4. Management of other B-cell malignancies
The regimen works by targeting cancer cells with cyclophosphamide while rituximab depletes B cells. Filgrastim is added to reduce the risk of neutropenia and allows for administration of full chemotherapy doses, particularly important in older patients.
02
Targets
Beyond the preview
Go deeper on cyclophosphamide + filgrastim + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + filgrastim + rituximab.